Cyteir Therapeutics Stock Fundamentals
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Shares Outstanding Analysis
Cyteir Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cyteir Therapeutics Shares Outstanding | 36 M |
Most of Cyteir Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyteir Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Cyteir Therapeutics has 36 M of shares currently outstending. This is 80.06% lower than that of the Biotechnology sector and 66.31% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.7% higher than that of the company.
Cyteir Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cyteir Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyteir Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyteir Therapeutics competition to find correlations between indicators driving Cyteir Therapeutics's intrinsic value. More Info.Cyteir Therapeutics is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Cyteir Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cyteir Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies. Cyteir Therapeutics is currently under evaluation in shares outstanding category among its peers.
Cyteir Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.14 | |||
Current Valuation | (20.89 M) | |||
Shares Outstanding | 36 M | |||
Shares Owned By Insiders | 6.63 % | |||
Shares Owned By Institutions | 76.83 % | |||
Number Of Shares Shorted | 319.73 K | |||
Price To Earning | 0.36 X | |||
Price To Book | 0.87 X | |||
Gross Profit | (16.59 M) | |||
EBITDA | (33.41 M) | |||
Net Income | (33.22 M) | |||
Cash And Equivalents | 166.4 M | |||
Cash Per Share | 4.71 X | |||
Total Debt | 889 K | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 19.95 X | |||
Book Value Per Share | 3.47 X | |||
Cash Flow From Operations | (25.79 M) | |||
Short Ratio | 3.07 X | |||
Earnings Per Share | (0.93) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 3.0 | |||
Number Of Employees | 46 | |||
Beta | 0.096 | |||
Market Capitalization | 108.71 M | |||
Total Asset | 153.23 M | |||
Retained Earnings | (138.11 M) | |||
Working Capital | 143.89 M | |||
Current Asset | 834.8 M | |||
Current Liabilities | 366.9 M | |||
Net Asset | 153.23 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |